Georgiamune
Georgiamune, Inc.
Regulating signaling pathways to restore immune homeostasis to fight cancer and autoimmune diseases.
georgiamune.com · Gaithersburg, MD
Funding event
The round itself, as filedInferred stageSeries C+
Sold of offered$92.7M of $132M
Filed2026-08-17
Days since filing48
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- Yes
- Date of first sale
- 2026-07-16
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Samir N. KhleifExecutive Officer · Director
- Sean ParkerDirector
- Elena VibochDirector
- Nancy OndovikDirector
- Paul BrownDirector
- Fredrick SchaufeldDirector
- Amy AbernethyDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged70.3% sold2.6 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-232
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- Scientist, Science & DiscoverySEP 24Science & Discovery · open 10 days
- Principal Scientist, Computational Biologist in Immunology, Science & DiscoverySEP 24Science & Discovery · open 10 days
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.